Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Essential tremor
- Focus Therapeutic Use
- Sponsors Merz Pharmaceuticals GmbH
- 20 Dec 2023 Status changed from active, no longer recruiting to completed.
- 16 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 May 2023.